|
|
|
|
Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 48 Weeks After the End of Treatment From an Interim Analysis of a Randomized Phase 3 Study, MYR301
|
|
|
AASLD Nov 15-19, 2024
Soo Aleman1, Maurizia Brunetto2,3, Antje Blank4, Pietro Andreone5, Pavel Bogomolov6, Vladimir Chulanov7, Nina Mamonova8, Natalia Geyvandova9, Viacheslav Morozov10, Olga Sagalova11, Tatyana Stepanova12, Grace M Chee13,
Dmitry Manuilov13, Sarah Arterburn13, Audrey H Lau13, Anu Osinusi13, Florence Christian-Cox13, Frank Duff13, Julian Schulze zur Wiesch14, Markus Cornberg15, Stefan Zeuzem16, Heiner Wedemeyer15, Pietro Lampertico17,18
|
|
|
|
|
|
|